This study was designed to test the hypothesis that plasma concentrations of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9), two enzymes that share similar substrate specificity (collagen type IV and V), possibly related to vascular remodelling, are altered in essential hypertension. The second aim of the study was to assess whether chronic antihypertensive treatment with the calcium channel blocker amlodipine would normalize these alterations. To test this hypothesis, we measured plasma concentrations of active MMP-2 and MMP-9 in 42 patients with never-treated essential hypertension and in 25 normotensive control subjects. Measurements were repeated after 6 months of treatment with the calcium channel blocker amlodipine. Baseline values of MMP-2 and MMP-9 were decreased (P ¼ 0.01 and 0.002, respectively) in hypertensive patients compared with normotensives. Hypertensive patients with systemic vascular resistances o1440 dyn s/cm 5 exhibited higher values of MMP-2 (P ¼ 0.005) and MMP-9 (P ¼ 0.001) than hypertensive patients with systemic vascular resistances 41440 dyn s/cm 5 . Treated patients attained a nonsignificant increase in MMP-2 plasma concentrations, but a significant increase in MMP-9 plasma concentrations (P ¼ 0.01) compared to respective values before treatment. In conclusion, these findings suggest that plasma concentrations of active MMP-2 and MMP-9, mainly related to vascular extracellular matrix metabolism, are depressed in patients with essential hypertension. A 6 month treatment with amlodipine can normalize MMP-9 but not MMP-2 plasma concentrations. The hypothesis that antihypertensive treatment may modulate collagen metabolism remains to be determined by further studies.
Introduction
Arterial hypertension is associated with cardiac and vascular remodelling. In cardiac remodelling, the structural changes involve myocyte hypertrophy and excessive accumulation of extracellular matrix component, that is, fibrosis.
1 Fibrosis has detrimental functional consequences because it impairs myocardial stiffness and promotes arrhythmias. 2 Alterations in mechanical properties and structure in arteries have also been well documented in chronic essential hypertension. 3, 4 Mechanical changes of large arteries and resistance vessels may contribute to the cardiovascular complications of hypertension. 5, 6 Two processes, vessel remodelling and/or vessel hypertrophy, are responsible for the structural changes that have been reported in large arteries as well as in resistance vessels. 7, 8 Remodelling of the vessel can occur through rearrangement of the existing cellular and extracellular components of the arterial wall around a smaller vessel. Vessel hypertrophy involves vascular smooth muscle cell proliferation, hypertrophy and/or polyploidy, and deposition of extracellular matrix (ECM), which may be localized to a region or throughout the vessel wall.
The ECM is responsible for the three-dimensional spatial arrangement, necessary for the integrity and the metabolic function of the tissue in intercellular space. In hypertension, changes have been reported in the density of ECM components as well as alterations in ECM architecture and/or cell-ECM attachments, in both myocardium and vessels. 9, 10 The matrix metalloproteinase (MMP) proteolytic system and the natural tissue endogenous inhibitors (TIMPs) are involved in the regulation of ECM metabolism. Altered MMP and/or TIMP activity may modulate hypertension-related accumulation of ECM proteins in the myocardium and arteries. MMP modulation of ECM could also result, via integrin-mediated signalling, in cytoskeletal rearrangement of the vessel wall. 10 Recent data have shown abnormal degradation of collagen type I, the major form of collagen in hypertensive myocardial fibrosis, in patients with essential hypertension. 11 Furthermore, Brilla et al 12 have reported that the activity of MMP-1, but not MMP-2, is abnormally depressed in the left ventricle of hypertensive patients with left ventricular hypertrophy. Recently, the proteolytic activities of MMP-9 and TIMP-1 have been suggested to be depressed in hypertensive patients. 13 Interstitial collagenase, MMP-1, is capable of degrading structural or fibrillar collagens (types I-III). Gelatinases A (MMP-2) and B (MMP-9) are two enzymes that mainly digest denatured collagen (gelatins), elastin, fibronectin, laminin as well as collagens type IV and V, mainly found in the subendothelial basement membrane of the vessel wall. 10 This study was designed to test the hypothesis that plasma concentrations of vascular remodellingrelated MMP-2 and MMP-9 are altered in essential hypertension. For this reason, we measured plasma concentrations of active MMP-2 and MMP-9 in a case-control study in hypertensive patients and normotensive control subjects. We also assessed the effects of chronic antihypertensive treatment with the calcium channel blocker amlodipine on plasma concentrations of MMP-2 and MMP-9, in patients with mild-to-moderate essential hypertension before and after chronic treatment with the calcium channel blocker amlodipine.
Methods

Subjects
The study population consisted of 42 patients with never-treated mild-to-moderate hypertension and 25 normotensive control subjects who were matched for age and sex.
Arterial blood pressure was measured in the morning (10.30-11.30 am) after 10 min in the supine position, using a mercury column sphygmomanometer. The I and V phases of the Korotkoff sounds were used; three measurements were obtained on each occasion, at 5-min intervals, and averaged. Arterial hypertension was said to be present if the systolic blood pressure and diastolic blood pressure were X140 and X90 mmHg, respectively. All patients had essential hypertension documented by appropriate laboratory tests, and none had ever taken any antihypertensive treatment. Conditions that could influence plasma levels of MMP-2 and MMP-9, such as pulmonary fibrosis, hepatic fibrosis, rheumatoid arthritis, cancer, recent surgery, childbirth or steroid use, were excluded after a thorough consideration of medical history and examinations. We also excluded patients with overt coronary artery disease or other organic heart diseases as evidenced by clinical, electrocardiographic and echocardiographic criteria.
A total of 42 patients received amlodipine as treatment (range, 5-10 mg once daily) for 6 months. The therapeutic goal was to achieve systolic and diastolic blood pressure o140 and o90 mmHg, respectively.
The control population consisted of 25 subjects with blood pressure o140/90 mmHg in repeated measurements. They were all recruited from medical personnel. All subjects signed an informed consent form and the hospital ethics committee approved the protocol of the study.
Clinical studies
Echocardiographic study Two-dimensional, targeted M-mode and Doppler ultrasound recordings were obtained in each patient and in the control population. Two investigators performed the echocardiographic measurements. The interpretations of the two investigators agreed in 92%. Intraobserver variability was assessed by one investigator. The two readings were concordant in 97%. Left ventricular mass was calculated using the formula validated by Devereux and Reichec. 14 Left ventricular mass index was obtained by dividing left ventricular mass by body surface area. The presence of left ventricular hypertrophy (LVH) was established when the left ventricular mass index was 4111 g/m 2 for men and 106 g/m 2 for women. 15 Ejection fraction was calculated according to Quinones et al. 16 Cardiac output was calculated according to the following formula aortic annular cross-sectional area Â flow velocity integral of left ventricular outflow Â heart rate. 17 Systemic vascular resistance (SVR) was calculated as mean arterial blood pressure (1/3 pulse pressure+diastolic blood pressure) Â 80 divided by cardiac output, expressed in units of dynes Á second per centimeter 5 (normal range, 1170 7 270 dyn s/cm 5 ). 18 
Biochemical analysis
The general biochemical evaluation included plasma glucose concentration and plasma lipid profile, measurement of plasma electrolytes (potassium, sodium, chloride), plasma and urine creatinine. Blood samples were drawn in fasting conditions. Biochemical parameters were measured by routine laboratory methods. Renal clearance of creatinine was calculated as the product of urine flow rate and urine creatinine concentration divided by plasma creatinine concentration. Plasma samples to determine MMP-2 and MMP-9 were taken at the time of the clinical studies and stored at À401C for up to 6 months. The 6-month follow-up samples were analysed together with samples from the initial set-up. The plasma concentrations of active MMP-2 and MMP-9 were determined by a two-site ELISA method using commercial reagents from Amersham (RPN 2631 and RPN 2634, respectively). The intra-and interassay variations to determine MMP-2 levels were 5.4 and 17.9%, respectively. The sensitivity (lower detection limit) was 0.19 ng/ml. The intra-and interassay variations for determining MMP-9 levels were 3.4 and 20.7%, respectively. The sensitivity was 0.05 ng/ml.
Statistical analysis
Values were expressed as mean 7 SD. The null hypothesis that a group of values were normally distributed was tested by Shapiro-Wilks' statistic. Student's t-test for unpaired data was used to assess the statistical significance between hypertensive patients and normotensive control subjects, and between hypertensive patients with and without increased systemic peripheral resistance. Student's t-test for paired data was used to assess the statistical significance between hypertensive patients before and after treatment. Also, Student's t-test for unpaired data was used to assess the statistical significance between hypertensive treated patients and normotensive control subjects. A value of Po0.05 was considered to be statistically significant.
Results
Baseline findings
Clinical data
The clinical characteristics of normotensive control subjects and hypertensive patients are presented in Table 1 .
Plasma concentrations of active MMP-2 and MMP-9
Plasma concentrations of active MMP-2 and MMP-9 were decreased in hypertensive patients compared with normotensive control subjects (Figures 1 and 2 ).
Hypertensive patients with systemic vascular resistance o1440 dyn s/cm 5 exhibited higher values of active MMP-2 and MMP-9 than those observed in hypertensive patients with systemic vascular resistance 41440 dyn s/cm 5 ( Figure 3 ).
Findings after treatment
Clinical data As shown in Table 1 , arterial pressure was normalized in patients receiving amlodipine (Po0.05). Systemic vascular resistance was also normalized after the treatment period (Po0.05) ( Table 1) .
Plasma concentrations of active MMP-2 and MMP-9
The plasma concentration of active MMP-9 was increased after 6 months treatment with amlodipine ( Figure 2 ). No significant increase was observed in the plasma concentration of MMP-2 after 
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Discussion
In the present study, plasma concentrations of active MMP-2 and MMP-9 are shown to be abnormally decreased in patients with essential hypertension compared with the normotensive controls. Furthermore, hypertensive patients with SVR o1440 dyn s/cm 5 exhibited higher plasma concentrations of active MMP-2 and MMP-9 than patients with SVR 41440 dyn s/cm 5 . Another finding of this study was that MMP-9, but not MMP-2, concentration was significantly increased after treatment with amlodipine.
Recent experimental data demonstrate a decrease in matrix proteolytic activity in young and adult spontaneously hypertensive rats (SHR). 19 In the present study, we have shown that the plasma concentrations of active MMP-2 and MMP-9 are decreased in patients with essential hypertension compared with the normotensive controls. This finding is in agreement with previous reports that patients with untreated essential hypertension have depressed collagenase activity. Laviades et al 11 have reported diminished plasma concentrations of free MMP-1 and increased plasma concentrations of free TIMP-1 in patients with essential hypertension. Furthermore, in the same study, hypertensive patients with LVH exhibited lower plasma levels of MMP-1 than hypertensives without LVH. Brilla et al 12 have shown that the activity of MMP-1, but not MMP-9, was depressed in the left ventricle of hypertensives with LVH. 12 Recently, Li-Saw-Hee et al 13 reported that the proteolytic activities of MMP-9 and TIMP-1 are depressed in hypertensive patients.
On the contrary, significant increases in MMP-1 and MMP-9 levels have been observed in aneurysmal aortic specimens. 20 Also, recent studies have demonstrated a selective downregulation of TIMPs along with upregulation of MMP-9 and total gelatinolytic activity in failing hearts. 21 The specific substrate for MMP-2 and MMP-9, and especially their ability to degrade type IV and V collagens, suggests their critical role in vascular basement membrane metabolism. We have shown, as other authors, that lower plasma concentrations of these two specific metalloproteinases (MMP-2 and MMP-9) in patients with essential hypertension may suggest a possible role of these gelatinases for the mechanisms of vascular remodelling.
Another result of this study is that plasma concentrations of active MMP-2 and MMP-9 are more depressed in patients with SVR41440 dyn s/cm 5 .
The fundamental cause of increased peripheral resistance in essential hypertension is a decrease in lumen diameter of resistance vessels. In hypertension, the change in structure of resistance vessels that produce the decreased lumen size involves a contribution of two processes: eutrophic and hypertrophic remodelling. By modulating the ECM profile and interactions with adhesive receptors, diminished MMP activity may contribute to the remodelling of resistance vessels. So the present finding may suggest that in patients with higher SVR, the more depressed plasma levels of MMP-2 and MMP-9 could facilitate collagen accumulation in the vascular wall. 3 Another finding of the present study is that MMP-9, but not MMP-2, concentrations are increased in hypertensive patients treated with amlodipine. Analysis of the individual data shows that the intensity of these changes is independent of the antihypertensive efficacy of the drug. To our knowledge, this is the first study to demonstrate the effect of chronic antihypertensive treatment with a calcium channel blocker of the dihydropyridine type to plasma concentrations of active MMP-2 and MMP-9.
There are conflicting data in the literature regarding the effect of antihypertensive drugs in modifying the MMP/TIMP system. Laviades et al 11 have shown normalization of MMP-1 and TIMP-1 after 1-year treatment with the angiotensin-converting enzyme (ACE) inhibitor lisinopril. Conversely, Li-Saw-Hee et al 13 have recently reported that a short follow-up period (2 months) with antihypertensive treatment either with an ACE inhibitor enalapril or an angiotensin AT 1 receptor antagonist losartan did not alter significantly the levels of MMP-9 and TIMP-1. 13 Amlodipine has been demonstrated to increase the proteolytic activity of MMP-2 and to inhibit the transcription of TIMP-2 in both fibroblasts and vascular smooth muscle cells. 22 A possible regulatory mechanism of MMP-2 activation could be linked to changes of intracellular calcium concentration. [23] [24] [25] Nevertheless, the molecular mechanisms of the modifying effects of amlodipine on MMP proteolytic activity need to be elucidated by further studies.
Study limitations
The net level of proteinase activity is dependent on the relative concentrations of free active enzyme and inhibitor. In the present study, we have not evaluated the plasma concentrations of TIMP. However, we have estimated the active forms of MMP-2 and MMP-9 before and after antihypertensive treatment. Furthermore, the plasma markers measured in this study are not vascular tissue specific. Gelatinases A and B can hydrolyse a variety of connective tissue protein substrates, including collagens (mainly IV, V, VII and X), elastin and denatured collagens of all genetic origins. Nevertheless, their ability to degrade type IV and V collagens suggests their critical role in vascular basement membrane destruction.
In conclusion, the findings presented here suggest that plasma concentrations of active MMP-2 and MMP-9 are depressed in patients with essential hypertension. This may reflect abnormal extracellular matrix metabolism, which could contribute to the cardiovascular remodelling. Antihypertensive treatment with the calcium channel blocker amlodipine significantly affected plasma levels of active MMP-9. The hypothesis that antihypertensive drugs may modulate collagen metabolism remains to be determined by further studies.
